@article{ajmcr202210105,
author={{Barbosa, In¨ºs and Pinto, Ezequiel and Munoz, Maria Gra?a Sequeira and Nascimento, Tania and Pais, Sandra},
title={Clinical Outcomes in Rheumatoid Arthritis due to Tocilizumab Stock-out during COVID-19 Epidemics: A Short Case Series Report},
journal={American Journal of Medical Case Reports},
volume={10},
number={10},
pages={271--273},
year={2022},
url={http://pubs.sciepub.com/ajmcr/10/10/5},
issn={2374-216X},
abstract={This short case-series reports a 6-month follow up of 5 rheumatoid arthritis patients (2 males, 3 females) 60 years-old or above, with Tocilizumab treatment which was discontinued due to stock off in July 2021. Patients switched treatment to other DMARD (Upadacitinib, Baricitinib, or Certolizumab pegol). We report clinical data and the Disease Activity Score for Rheumatoid Arthritis. Upadacitinib, Baricitinib, and Certolizumab appear therapeutically equivalent to Tocilizumab in a 6-month follow-up.},
doi={10.12691/ajmcr-10-10-5}
publisher={Science and Education Publishing}
}